What does Hims & Hers Health do?
Hims & Hers Health, Inc., listed on the New York Stock Exchange under HIMS, began in 2017 by simplifying care for sensitive, recurring conditions. It has expanded beyond hair loss and sexual health. The official company overview describes a platform linking consumers with licensed providers, personalized plans, prescription and non-prescription products, follow-up, and fulfillment.
Which health needs sit inside the platform?
The portfolio spans sexual health, hair loss, dermatology, mental health, weight management, hormone health, menopause, testosterone care, and laboratory testing. The 2025 Form 10-K also identifies sleep, fertility, diabetes, cholesterol, hypertension, and post-traumatic stress disorder as potential areas. Many are chronic or recurring needs that can support longer relationships.
Why is the model more than a telehealth app?
Hims & Hers coordinates demand generation, clinical workflow, electronic medical records, product selection, pharmacy operations, shipping, and longitudinal data. Its clinical-excellence framework emphasizes licensed providers and structured quality systems. Integration can improve convenience and personalization, but it also makes clinical quality, supply continuity, privacy, and regulation core operating risks.
| Business layer | What Hims & Hers controls or coordinates | Why it matters |
|---|---|---|
| Consumer acquisition | Brand, digital advertising, education, and onboarding | Creates a direct relationship instead of relying mainly on insurer or employer referrals. |
| Clinical layer | Affiliated medical groups, provider software, and treatment protocols | Makes the model clinically credible but introduces professional-practice and licensing constraints. |
| Commerce and fulfillment | Subscriptions, pharmacies, packaging, shipping, and customer support | Supports recurring revenue and faster product iteration, while increasing capital and execution needs. |
How does Hims & Hers make money?
The company primarily sells recurring care and health products directly to consumers, usually on 30- to 360-day shipment cadences. Longer cadences can improve unit economics by reducing fulfillment events. Revenue is generally recognized when products ship, and customers can cancel or pause, so subscribers are relationships to retain rather than contractual backlog.
Where does revenue come from?
Hims reports one operating segment, so separate profits for weight loss, sexual health, dermatology, or mental health are not disclosed. It does disclose geography and historically separated online from wholesale revenue. In FY2025, online revenue was $2.311B versus $36.2M wholesale, or about 98.5% online. Owning the customer relationship is attractive, but makes advertising, conversion, retention, and uptime disproportionately important.
| Revenue mechanism | Economic logic | Main analytical question |
|---|---|---|
| Recurring product subscription | Product revenue plus convenience from scheduled refills | Can retention and gross profit cover customer acquisition and fulfillment costs? |
| Membership and care access | Ongoing access, monitoring, or benefits attached to a treatment pathway | Does membership deepen engagement without adding disproportionate clinical cost? |
| Wholesale | Products sold through third-party retail channels | Can broader distribution add awareness without weakening direct-channel economics? |
| Principal versus agent arrangements | Gross revenue when Hims controls the product; net revenue when it primarily arranges access | How much reported growth reflects product economics versus platform fees? |
Which revenue mix matters most?
Personalized offerings exceeded 70% of U.S. revenue in FY2025, up from roughly half in FY2024, while Hers approached 40% of U.S. revenue, versus less than 30% a year earlier. A majority of FY2025 U.S. revenue also came from non-GLP-1 offerings. These disclosures show a broader model than the original men’s-health brand or a single weight-loss product cycle.
What does Hims & Hers’ latest quarter reveal?
The first-quarter 2026 results and Form 10-Q show growth amid a difficult mix and regulatory transition. Revenue was $608.1M, up 4%; subscribers reached 2.584M, up 9%; and monthly revenue per average subscriber fell 6% to $80. Customer count therefore expanded faster than monetization.
What changed in Q1 2026?
| Metric | Q1 2026 | Year-over-year signal | Interpretation |
|---|---|---|---|
| Revenue | $608.1M | Up 4% | Growth slowed during the U.S. weight-loss and cadence transition. |
| U.S. revenue | $529.9M | Down 8% | Shorter fulfillment cycles changed revenue timing. |
| Rest-of-world revenue | $78.2M | Up 969% | Acquired international operations became meaningful. |
| Adjusted EBITDA | $44.3M | Lower | Gross-margin pressure and investment reduced adjusted profitability. |
| Operating cash flow | $89.4M | Lower | Cash generation remained positive despite the GAAP loss. |
| Cash and short-term investments | $750.9M | March 31, 2026 balance | Liquidity supports investment, acquisitions, and transition costs. |
Why did margin and GAAP earnings weaken?
Product mix, fulfillment cadence, and the U.S. weight-loss transition pressured profitability. The quarter included about $28.5M of restructuring and inventory write-down costs, helping explain why GAAP earnings weakened even though operating cash flow remained positive.
Which turning points shaped Hims & Hers today?
Each major turning point added a layer to the present model: brand, public capital, pharmacy capabilities, weight-loss demand, international infrastructure, diagnostics, or manufacturing.
-
2017Hims launched around stigmatized men’s health needs. The direct, discreet consumer proposition remains the core acquisition logic.
-
2018–2019The Hers brand broadened the addressable market and established the two-brand architecture that now drives a much larger female-health mix.
-
2021The Oaktree combination supplied public capital. The Apostrophe acquisition added dermatology and compounding-pharmacy capabilities.
-
2024Weight-loss offerings, including access to compounded GLP-1 treatments, accelerated customer growth and raised the importance of pharmacy regulation and supply economics.
-
2025ZAVA, Livewell, and related assets expanded the platform into Europe and Canada. The company also acquired a U.S. peptide facility and increased investment in internal fulfillment.
-
January 2026The YourBio acquisition added capillary blood-sampling technology. The accounting purchase price was approximately $153.0M, signaling a move toward diagnostics and more preventive, data-rich care.
-
March–June 2026Hims shifted U.S. weight loss toward branded GLP-1 access and limited compounding, then completed the Eucalyptus acquisition, adding operations in Australia, the United Kingdom, Germany, Canada, and Japan.
Each capability can improve personalization and lifetime value, but also increases fixed cost, integration risk, regulation, and balance-sheet commitments. Hims is becoming a global care-and-commerce infrastructure company rather than an asset-light digital front end.
What creates Hims & Hers’ competitive advantage?
The advantage is not an exclusive medicine or license. It is the combination of brand, acquisition, clinical workflow, personalization, and fulfillment. Hims can identify demand, move a qualified consumer into care, fulfill treatment, observe behavior, and offer adjacent services within one journey.
How does the closed-loop model compound data and convenience?
By FY2025, the platform had facilitated more than 50 million consultations, and Q1 2026 subscribers exceeded 2.5 million. More interactions can improve onboarding, treatment selection, adherence, and support. Owned infrastructure adds control over formulation, packaging, shipment timing, and experimentation.
Where does the moat remain vulnerable?
Switching costs are limited when treatments are standardized. Customer acquisition costs were $798.5M in FY2025, and marketing represented 39% of revenue, improved from 46% in FY2024 but still substantial. The moat therefore depends on acquisition payback, repeat purchasing, cross-category use, and trust.
Who competes with Hims & Hers?
Hims does not disclose one market-share figure because it competes across overlapping markets: traditional providers and pharmacies, telehealth platforms, large retailers, laboratories, pharmaceutical companies, and manufacturer-led access channels. Representative rivals include Ro, Teladoc, Amazon One Medical and Amazon Pharmacy, plus drug manufacturers selling through direct access programs.
Which rival groups pressure each layer?
| Competitive group | Examples | Pressure on Hims & Hers | Hims response |
|---|---|---|---|
| Consumer telehealth platforms | Ro and category-focused digital clinics | Similar acquisition channels, subscriptions, and condition portfolios | Broader brand reach, personalization, and more owned infrastructure |
| Large integrated platforms | Amazon One Medical and Amazon Pharmacy | Scale, logistics, consumer trust, and bundled services | Specialized journeys, brand tone, and faster condition-specific product design |
| Incumbent virtual care | Teladoc and health-plan channels | Employer distribution, insurer relationships, and broad clinical coverage | Direct consumer ownership and product-commerce integration |
| Manufacturers and pharmacies | Branded drug access programs and retail pharmacy networks | Lower-friction access to branded medications and strong supply relationships | Multi-condition care, personalization, and a unified consumer experience |
Rivalry and substitutes are abundant, while supplier power rises when few manufacturers control important drugs. Hims is strongest when experience and care continuity matter; it is weakest when every provider offers the same treatment at similar speed.
How financially strong is Hims & Hers?
FY2025 showed both scale and the cash cost of vertical integration. Revenue increased 59% to $2.348B, net income reached $128.4M, and free cash flow was $57.4M as investment accelerated.
What does annual cash generation say?
Free cash flow equals operating cash flow minus capital expenditures and capitalized software. FY2025 conversion was about 19%. Internal pharmacies, manufacturing, diagnostics, and fulfillment may support future margins, but a DCF cannot assume accounting profit converts into cash without substantial reinvestment.
What does the convertible financing change?
At March 31, 2026, Hims carried $974.1M of 2030 convertible notes against $750.9M of cash and short-term investments. In May it issued another $402.5M of 0% notes due 2032, disclosed in the May 2026 Form 8-K. The structure limits current cash interest but adds refinancing and dilution sensitivity.
| Financial driver | Official figure | Period | Research implication |
|---|---|---|---|
| Gross margin | 74% | FY2025 | High product gross margin, but below 79% in FY2024 as mix and fulfillment changed. |
| Marketing intensity | 39% of revenue | FY2025 | The model remains acquisition-heavy even after improving from 46% in FY2024. |
| Capital investment | $242.6M | FY2025 | Property, equipment, intangibles, and internal software consumed most operating cash flow. |
| Current liquidity | $750.9M | March 31, 2026 | Meaningful liquidity, but below year-end after acquisitions and investment. |
| Convertible principal | $1.403B | After May 2026 issuance | Adds strategic funding while increasing long-term capital-structure sensitivity. |
Who owns Hims & Hers stock, and why does control matter?
Economic ownership and voting control differ sharply. Under the 2026 proxy, Class A carries one vote per share, while Class V carries 175 votes and converts one-for-one. Andrew Dudum owned all Class V shares and held 87.73% of total voting power.
Founder control versus economic ownership
| Holder or group | Economic stake | Total voting power | Why it matters |
|---|---|---|---|
| Andrew Dudum | Founder with Class A and all Class V shares | 87.73% | Can strongly influence directors, strategy, financing, and major corporate actions. |
| BlackRock | 10.35% of Class A | 1.36% | Large economic holder with limited control under the dual-class structure. |
| Capital World Investors | 6.43% of Class A | Less than 1% | Institutional ownership matters economically more than it does for voting control. |
What does governance signal?
The proxy presented nine director nominees, with David Wells as lead independent director, plus audit, compensation, nominating, and risk committees. Oversight remains subordinate to concentrated voting power. The research question is whether control sustains coherent long-term strategy or weakens accountability as acquisitions and regulation become more complex.
What are the biggest growth opportunities?
The best opportunities reuse brand, clinical, software, and fulfillment infrastructure across more conditions and countries, raising retention or revenue per customer without equivalent growth in marketing and compliance cost.
Specialty expansion and preventive care
International scale after Eucalyptus
Eucalyptus had served more than 850,000 customers by May 2026 and brought platforms in five countries. The structure included $240M cash at closing, $710M deferred over 18 months, and up to $200M of earnouts. International growth is therefore a major operating and financing commitment.
International scale can diversify the U.S.-heavy base, but prescribing rules, pharmacy operations, consumer behavior, and reimbursement differ by country. Success requires local operating depth, not merely exporting the U.S. playbook.
What risks could weaken the model?
The risks are interconnected: regulation changes product availability, mix changes margin, acquisitions raise integration cost, marketing inflation weakens unit economics, and service or clinical failures damage revenue and trust. Each risk should be mapped to a financial line.
Why is GLP-1 and compounding regulation central?
In February 2026, the FDA said it intended to act against mass-marketed non-FDA-approved GLP-1 products, including products promoted by Hims. The official statement stressed that compounded drugs are not FDA-approved. Hims then announced a U.S. weight-loss shift toward broader branded access, membership, and more limited compounding.
Branded products can have different pricing and margin economics than compounded treatments. Regulation can therefore affect revenue, gross margin, inventory, and marketing simultaneously; the $28.5M Q1 2026 charge shows that transmission.
Which operating risks deserve the closest attention?
| Risk | Financial line affected | What to monitor |
|---|---|---|
| Regulatory limits on compounding, telehealth, or marketing | Revenue, gross margin, inventory charges, legal expense | Product mix, FDA actions, state rules, and disclosure of material remediation costs |
| Acquisition and international integration | Operating expense, goodwill, cash, deferred consideration | Rest-of-world growth, local retention, integration milestones, and impairment indicators |
| Customer acquisition inflation | Marketing expense and contribution margin | Marketing as a share of revenue, subscriber additions, and revenue per subscriber |
| Supplier, pharmacy, cloud, or logistics disruption | Revenue, shipping cost, refunds, and working capital | Fulfillment speed, product availability, service incidents, and inventory balance |
| Privacy, cybersecurity, or clinical-quality failure | Revenue, legal cost, insurance, and brand value | Regulatory investigations, litigation, customer complaints, and retention trends |
| Convertible debt and share issuance | Interest, diluted shares, refinancing risk, and enterprise value | Cash settlement choices, conversion thresholds, deferred acquisition payments, and maturity planning |
Which KPIs best explain Hims & Hers’ performance?
The dashboard must connect growth to unit economics; subscriber count can rise while monetization deteriorates.
Together, the metrics trace the value chain from acquisition to subscribers, monetization, gross margin, operating leverage, and free cash flow.
What is the key takeaway for valuation and research?
Hims is testing whether a consumer brand can become the organizing layer for recurring healthcare. Scale, personalization, and integrated fulfillment support the story; founder control, acquisition commitments, regulation, margin volatility, and capital intensity constrain it. It is a hybrid of subscription commerce, care delivery, and pharmacy infrastructure.
Which DCF variables matter most?
What should researchers monitor next?
- Whether U.S. revenue returns to growth after the weight-loss transition and shorter shipping cadence.
- Whether gross margin recovers from approximately 65% in Q1 2026 without sacrificing branded access or clinical quality.
- How Eucalyptus affects international growth, operating expense, deferred consideration, and cash generation.
- Whether marketing intensity falls below the FY2025 level of 39% while subscriber growth remains healthy.
- Whether diagnostics and multiple-condition adoption lift retention and revenue per subscriber.
- How the company funds acquisitions and infrastructure while managing more than $1.4B of convertible principal.
- Whether founder control supports disciplined capital allocation as complexity rises.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.